Filing Details
- Accession Number:
- 0001562180-18-004218
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-10-15 17:54:19
- Reporting Period:
- 2018-10-11
- Accepted Time:
- 2018-10-15 17:54:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1560241 | G1 Therapeutics Inc. | GTHX | Pharmaceutical Preparations (2834) | 263648180 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1706847 | A. Mark Velleca | C/O G1 Therapeutics, 79 Tw Alexander Dr. 4501 Research Commons, Suite 100 Research Triangle Park NC 27709 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-10-11 | 10,000 | $0.39 | 19,000 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2018-10-15 | 5,000 | $3.72 | 24,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-10-15 | 2,163 | $40.90 | 21,837 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-10-15 | 2,837 | $42.01 | 19,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2018-10-11 | 10,000 | $0.00 | 10,000 | $0.39 |
| Common Stock | Stock Options (Right to Buy) | Disposition | 2018-10-15 | 5,000 | $0.00 | 5,000 | $3.72 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 389,286 | 2024-05-09 | No | 4 | M | Direct | |
| 124,433 | 2025-12-21 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- The price represents the weighted average price with a low of $40.60 and a high of $41.10. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 and 3 to this Form 4.
- The price represents the weighted average price with a low of $41.95 and a high of $42.29.
- All shares underlying this option have vested.
- The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Billionaire Hedge Funds
